Prevention, Early Detection, and Interception最新文献

{"title":"Abstract 2428: New school health care: Utilizing technology in the treatment and support of women with breast cancer in the ambulatory setting","authors":"T. Jones, A. J. Paladino, G. Vidal, R. Krukowski, J. Graff, Ryan Blue, I. Graetz, L. Schwartzberg, M. Koçak, Janeane N. Anderson","doi":"10.1158/1538-7445.SABCS18-2428","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2428","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86646358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 5090: Epitope mapping of mouse TERT for vaccine development","authors":"Yurong Song, J. Marshall, T. Kerr, L. Pinto, S. Sei, R. Shoemaker","doi":"10.1158/1538-7445.AM2019-5090","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5090","url":null,"abstract":"Telomerase reverse transcriptase (TERT) is one of two essential components of telomerase, an enzyme complex that generates and maintains telomeres. Telomerase is expressed mainly in embryonic and adult stem cells. Telomere biology has recently been implicated in the pathogenesis of a variety of diseases, and mutations in telomerase components result in a predisposition to solid malignancies. More recent findings show that TERT is not only expressed in late stage primary tumor cells and metastatic cells, but also expressed in incipient cancer stem cells and/or tumor-initiating cells, indicating that TERT has essential roles at every stage of tumorigenesis. However, the clinical benefit of a TERT (hTERT)-targeting vaccine, given as a single agent or in combination with chemotherapeutic agents, has been limited in patients with advanced cancer, possibly due to insufficient epitope coverage as well as tumor-induced immune suppression. Thus, targeting TERT in tumor-initiating cells in early stage lesions may be more effective in preventing cancer development and progression. To develop cancer preventive TERT vaccines, novel immunogenic epitopes must be first identified and evaluated in a relevant preclinical model of tumorigenesis. The goal of this project is to identify the epitopes of mouse TERT with high immunogenicity using MHC I-peptide binding assay by flow cytometry analysis. The in vitro peptide-induced MHC Class I stabilization assay was carried out using RMA/S cell line, which was derived from a Rauscher leukemia virus-induced C57BL/6 T cell lymphoma and is deficient in transporter associated with antigen processing (TAP). Results of screening the overlapping peptide library will be presented. Funded by NCI Contract No. HHSN261200800001E Citation Format: Yurong Song, Jason Marshall, Travis Kerr, Ligia Pinto, Shizuko Sei, Robert Shoemaker. Epitope mapping of mouse TERT for vaccine development [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5090.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"85 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80461414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 2426: Familial reinforcement and family history interact to influence knowledge about pancreatic cancer","authors":"Mariam Stevens, D. Mikhail, A. Hernández, Sarah E Fagan, K. G. Chaffee, G. Petersen","doi":"10.1158/1538-7445.SABCS18-2426","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-2426","url":null,"abstract":"","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89641271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 652: Racial/ethnic differences in BRCA testing and test results among adult women","authors":"F. Guo, E. Fuchs, A. Berenson, Y. Kuo","doi":"10.1158/1538-7445.AM2019-652","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-652","url":null,"abstract":"Introduction: BRCA mutation testing has been recommended for targeted, individualized cancer prevention and treatment among women whose family histories or ethnic backgrounds are associated with increased risks for BRCA mutations. This study was to assess BRCA testing in different racial/ethnic groups in the US. Methods: We used data from ClinformaticsTM Data Mart (CDM) Electronic Health Records. We included 134,827 women 18-65 years old with BRCA testing results from 1/1/2015-9/1/2017. BRCA testing rates and test result positive rates were calculated by race/ethnicity. Women with positive test results had a high risk for developing susceptible cancers - breast or ovarian cancer. As we only had data through 9/1/2017, we calculated annual test rates based on data in 2016. Results: The BRCA mutation test rate in 2016 was highest among non-Hispanic Whites (582 per 100,000), while it was 313 per 100,000 in non-Hispanic Black women, 310 per 100,000 in Hispanic Women, and 281 per 100,000 in women of other races/ethnicities. Percentage of positive results was lowest among non-Hispanic White women tested (75.7%), and highest among non-Hispanic Black test takes (85.1%). After adjusting for age, region of residence, education, income, and family history of breast or ovarian cancer, adjusted odds ratio for having a positive test among non-Hispanic Black women tested vs. non-Hispanic White women tested was 1.71, 95% confidence interval 1.61-1.82, and adjusted odds ratio for Hispanics vs non-Hispanic Whites was 1.21, 95% confidence interval 1.13-1.31. Conclusions: There are significant differences in test utilization and test results. Test utilization was highest in non-Hispanic Whites, who were also less likely to have a positive test result. Non-Hispanic Black women tested were more likely to have a positive test result, suggesting a more stringent test selection criteria for this underserved population. Citation Format: Fangjian Guo, Erika L. Fuchs, Abbey B. Berenson, Yong-Fang Kuo. Racial/ethnic differences in BRCA testing and test results among adult women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 652.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79237599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 1612: The effect of docosahexaenoic acid on androgen-dependent and androgen-independent prostate tumors in combination with abiraterone and enzalutamide","authors":"Andre R. Cooper, Irvin V. Ma, A. Shao, Prem Kumar, R. Pardini","doi":"10.1158/1538-7445.AM2019-1612","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-1612","url":null,"abstract":"Standard treatments for prostate cancer typically involve androgen deprivation therapy (ADT). In later stages of prostate cancer, the tumor typically evolves to become insensitive to ADT, otherwise known as castration-resistant prostate cancer (CRPC). Despite being hormone-insensitive, CRPC has been shown to respond to both abiraterone and enzalutamide. Although both treatments deprive the tumor of androgens, they both display different mechanisms of action. Abiraterone inhibits androgen production, and enzalutamide acts by interrupting the binding of androgens to the androgen receptor. Studies in our laboratory have shown that docosahexaenoic acid (DHA; C22:6, n-3), a long chain omega-3 polyunsaturated fatty acid (PUFA), inhibits tumorigenesis in both androgen-dependent (LNCaP) and androgen-independent (PC-3, DU145) prostate cancer cell lines in culture. Moreover, in vivo studies with n-3 supplementation have been shown to significantly reduce PC-3 and DU145 tumor growth compared to corn oil diets rich in linoleic acid (C18:2, n-6). With evidence suggesting that n-3 PUFA dietary supplementation can inhibit tumorigenesis in CRPC, this study investigated the efficacy of DHA in combination with both abiraterone and enzalutamide in a subset of prostate tumor phenotypes in vitro. PC-3 and LNCaP cell viability were reduced with DHA in combination with either enzalutamide or abiraterone compared to primary treatments of each. These results suggest that DHA enrichment can augment abiraterone and/or enzalutamide therapy with androgen-dependent and androgen-independent prostate tumors in vitro. The results of this study provide preliminary evidence of the effectiveness of nutritional supplementation in conjunction with cancer therapeutics, and it will serve as a prelude to a pilot clinical trial evaluating the effects of nutritional supplementation with high levels of omega-3 fatty acids on enzalutamide inhibition of CRPC. Citation Format: Andrew R. Cooper, Irvin V. Ma, Andy Shao, Prem Kumar, Ronald S. Pardini. The effect of docosahexaenoic acid on androgen-dependent and androgen-independent prostate tumors in combination with abiraterone and enzalutamide [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1612.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"36 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78047511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract LB-052: Detection of rare, deleterious clonal mutations during unrelated allogeneic hematopoietic stem cell transplants using an error correction pipeline for NGS","authors":"W. H. Wong, A. Young, T. Druley","doi":"10.1158/1538-7445.AM2019-LB-052","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-LB-052","url":null,"abstract":"While next-generation sequencing (NGS) has transformed our ability to characterize the genome, it is limited in detection of rare mutations due to a high error rate of ~0.5-2.0%. We have developed an error correction pipeline and previously demonstrated that our process is capable of detecting variants as rare as 1:10,000 or 0.0001 VAF. Using our error correction pipeline, we have recently identified leukemia-related hematopoietic clones in a cohort of young healthy bone marrow donors (median age 26). In the context of allogeneic hematopoietic stem cell transplantation (HSCT), we sought to determine whether these detected leukemia-related clones of donor origin selectively engraft and correlate with transplant-related morbidities in recipients post-HSCT. Genomic profiles of pre-transplant donor samples were compared to the genomic profiles of corresponding recipient samples post-HSCT. Results show that two-thirds of the healthy donor samples harbor deleterious hematopoietic clones and that these specific clones are significantly more likely to engraft compared to benign clones. We also found that 75% of recipients who had at least one persistently engrafted, deleterious mutation developed chronic GvHD versus 50% of those without persistently engrafted clones with deleterious mutations. In comparing the results from our error correction pipeline and conventional short tandem repeat (STR) testing for donor-patient chimerism, we showed that our method provides a highly sensitive approach to both screening for donors without deleterious clones and monitoring residual disease in recipients following hematopoietic stem cell transplants (HSCT). Furthermore, the clinical implications of these results warrant a large-scale study using our error correction pipeline to detect rare variants in HSCT. Citation Format: Wing Hing Wong, Andrew Young, Todd Druley. Detection of rare, deleterious clonal mutations during unrelated allogeneic hematopoietic stem cell transplants using an error correction pipeline for NGS [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-052.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"35 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77598421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 5066: Chemoprevention of breast cancer by targeting glucose metabolism with HJC0152","authors":"Hyejin Kim, Jiabin Dong, Lili Wang, Jimin Xu, Dan Zhang, R. Yan, H. Zou, Haiying Chen, Xi Liu, Yun Zhu, Yu Xue, Jia Zhou, Q. Shen","doi":"10.1158/1538-7445.AM2019-5066","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5066","url":null,"abstract":"Most mammalian cells use glucose as the primary fuel source, which is metabolized via glycolysis to pyruvate and further transferred into mitochondria for generating ATP through the Krebs cycle under normal condition. However, metabolism is characteristically reprogrammed in cancer cells or highly proliferative cells with a preferential ATP production through generating lactate by lactate dehydrogenase (LDH/LDHA), referred to as the Warburg effect or metabolic reprogramming toward anaerobic glycolysis. Efficient control of energy metabolism is the key to maintaining metabolic homeostasis, while disturbance in energy balance provokes diseases such as obesity, diabetes and cancer. However, the mechanisms underlying efficient energy metabolic homeostasis and breast cancer development are poorly understood. The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) is activated downstream of many cytokines and growth factor receptors. STAT3-targeting genes and their functions vary depending on the cellular context, primarily in correlation with cell survival and proliferation. Recently, reports show that active STAT3 with phosphorylation at Y705 residue plays an important role in regulating energy metabolism via transcriptional induction of its well-recognized transcriptional target HIF-1α. HJC0152, a novel small-molecule glucose metabolism modulator, was proprietarily developed using a combination approach of structure-based drug design strategies and molecular modeling techniques in our attempt to develop orally bioavailable non-peptide STAT3 inhibitors for anticancer use. A panel of mammary epithelial cells and breast cancer cells treated with HJC0152 exhibited suppressed cell growth and induced apoptosis in vitro. Intriguingly, HJC0152 reduces glucose uptake and Glut1 protein level. In addition, HJC0152 treated BC cell line showed decreased protein level of glycolytic enzymes including HK2, PFKL, ALDOA, PDHK, PKM2, LDHA and important metabolism regulator HIF-1α in a time-dependent manner. Furthermore, HJC0152 has significant in vivo efficacy in reducing/preventing mammary tumor development in transgenic mouse models of estrogen receptor (ER)-negative breast cancer. These results provide a rationale to develop HJC0152 as a promising drug candidate and preventive therapy for breast cancer and other cancers with aberrant glucose metabolism. In addition, HJC0152 can serve as a molecular probing tool for elucidating the key factors driving the development of breast cancer in the context of metabolic dysregulation and diseases. This work was supported by grant R01CA226001 from the NIH/NCI. Citation Format: Hyejin Kim, Jiabin Dong, Lili Wang, Jimin Xu, Dan Zhang, Ruping Yan, Hao Zou, Haiying Chen, Xi Liu, Yun Zhu, Yu Xue, Jia Zhou, Qiang Shen. Chemoprevention of breast cancer by targeting glucose metabolism with HJC0152 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-A","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81124893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 4213: Stool-derived eukaryotic RNA (seRNA) assay for noninvasive detection of colorectal cancer and high-risk adenomas","authors":"Erica K. Barnell, Yiming Kang, Katie M. Campbell, K. Kruse, A. Barnell, E. Wurtzler","doi":"10.1158/1538-7445.SABCS18-4213","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4213","url":null,"abstract":"Colorectal cancer (CRC) is the second leading cause of cancer related deaths in the United States. The high mortality rate for CRC is largely attributable to the frequency of late-stage diagnoses, caused by low patient compliance with screening guidelines. A novel nucleic acid extraction method that isolates stool-derived eukaryotic RNA (seRNA) has permitted development of a colorectal cancer stool diagnostic test (CRC-SDT) that uses a fecal immunochemical test (FIT) and 11 seRNA transcripts to serve as a reliable and noninvasive screening alternative to lower mortality associated with CRC. Stool samples were obtained from 190 individuals prior to undergoing a screening colonoscopy. Patients were diagnosed as either having colorectal cancer, having high-risk adenomas (high-grade dysplasia, villous growth pattern, or >1.0cm in size), or healthy (low-risk adenomas, benign polyps, and/or no findings on a colonoscopy). FITs were obtained for each sample. Samples that had a positive FIT were considered positive for the CRC-SDT. Samples that had a negative FIT underwent seRNA isolation, library preparation (Illumina TruSeq Targeted RNA) and subsequent sequencing (Illumina NextSeq 550). A random forest model was built using 11 transcripts that were differentially expressed (log2 fold-change > 1; ANOVA p Citation Format: Erica K. Barnell, Yiming Kang, Katie M. Campbell, Kimberly R. Kruse, Andrew R. Barnell, Elizabeth M. Wurtzler. Stool-derived eukaryotic RNA (seRNA) assay for noninvasive detection of colorectal cancer and high-risk adenomas [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4213.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"10 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86555902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 5067: Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinomain situbreast cancer","authors":"N. Shan, Min-Ji Bak, L. Cai, R. Wernyj, Davit Sargsyan, David Cheng, A. Minden, A. Kong, N. Suh","doi":"10.1158/1538-7445.AM2019-5067","DOIUrl":"https://doi.org/10.1158/1538-7445.AM2019-5067","url":null,"abstract":"Ductal carcinoma in situ (DCIS), the pre-invasive form of breast cancer, counts for one out of every five new breast cancer diagnoses. About one-third to half of the DCIS patients will progress to invasive breast cancer within 10 years of initial diagnosis. The disappearance of myoepithelial layer and disruption of the basement membrane are the hallmarks of transition from DCIS to invasive ductal carcinoma (IDC). Our laboratory has previously shown that vitamin D compounds decreased the MCF10DCIS.com xenograft tumors and inhibited the invasive transition from DCIS to IDC. We have also demonstrated that vitamin D compounds inhibited mammosphere formation by targeting breast cancer stem-like population and putative stem cell markers in MCF10DCIS cells. However, the key molecular mechanisms that govern the transition from DCIS to IDC are yet to be elucidated. In this study, we have performed RNA sequencing analysis of mammospheres treated with vitamin D compounds to identify potential genes that regulate breast cancer stemness and potentially the progression of DCIS to IDC. The mammosphere culture system has been shown to enrich stemness in tumor cells grown in low-attachment tissue culture plates. Upon treatment of mammospheres with vitamin D compounds, we identified down-regulation of genes that are involved in maintenance of breast cancer stem-like cells (e.g. GDF15, XBP1 and ALDH1A3), genes that mediate epithelial-mesenchymal transition, invasion and metastasis (e.g. LCNZ and S100A4), genes that confer breast cancer chemo-resistance (e.g. NGFR, PPP1R1B1, and AGR2) and genes that serve as biomarkers of basal breast cancer (e.g. NGFR). We also observed the up-regulation of genes that are associated with basal-like phenotype (e.g. KRT6A and KRT5), genes that regulate breast tumorigenesis (e.g. EMP1) and genes that regulate breast cancer stem cell self-renewal (e.g. DICER1). Our data set encompasses over 20,000 genes, providing us with unbiased insight to understand the overall gene expression profiling in DCIS breast cancer stem cells treated with vitamin D compounds. Thus, this study helps us identify genes that are key drivers of breast cancer stemness and progression and those regulated by vitamin D compounds. Further mechanistic studies of these significant genes will elucidate the natural history of DCIS progression to IDC, and provide us with target genes to prevent breast cancer progression. (This project is funded by Busch Biomedical Grant, Rutgers University) Citation Format: Naing Lin Shan, Min Ji Bak, Li Cai, Roman Wernyj, Davit Sargsyan, David Cheng, Audrey Minden, Ah-Ng Tony Kong, Nanjoo Suh. Identification of key drivers of cancer stemness and progression regulated by vitamin D compounds in ductal carcinoma in situ breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 5067.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86487145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abstract 4216: The microbiota associated to cervical and anal HPV infections in a Hispanic population","authors":"Frances Vázquez-Sánchez, Gilmary Ortiz, A. P. Ortiz, F. Godoy-Vitorino","doi":"10.1158/1538-7445.SABCS18-4216","DOIUrl":"https://doi.org/10.1158/1538-7445.SABCS18-4216","url":null,"abstract":"Anogenital human papillomavirus (HPV) are the world’s most commonly diagnosed sexually transmitted infections and high-risk types are linked to dysplasia. Susceptibility to HPV infections is related to the microbial communities of these genital surfaces, which are interfaces between the host and environment. Microbes are a predicted cause of malignancies, revealing a tremendous potential of microbiome-related processes for cancer prevention and diagnostics. The cervix and anus share a susceptible transformation zone, characterized by a metaplastic epithelial site. In fact, in women, anal and cervical squamous intraepithelial lesions tend to occur concurrently, an observation that could be explained by the fact that anal and cervical HPV infections are strongly correlated. We hypothesized that bacterial communities may differ in the anus and cervix and may reveal populations associated to HPV infections in these two body sites. To test this hypothesis we characterized the microbiota of a cross-sectional population-based sample of Puerto Rican women (self-sampled) from the San Juan metropolitan (n=300 samples) and related them to anogenital HPV infections (HPV typing performed by PCR). The microbiota of resident cervical and anal bacterial communities was performed through sequencing of the 16S ribosomal RNA V4 region with the Illumina platform. Data was analyzed at first with QIIta, using the SILVA database as taxonomic reference, and community analyses were performed in QIIME and R. Significant differences in community structure (betadiversity) were found between cervical and anal communities (p-value = 0.001), but not according to HPV (p-value = 0.212) in any of the body sites. Indeed, overall anal communities were dominated by OTUs within Prevotella, Bacteroides and Clostridiales, while cervical samples were dominated by Lactobacillus and Bifidobacteraceae (Gardnerella). Despite the common core communities at each body site, cervical samples of HPV positive patients revealed an enrichment of Ureaplasma and Prevotella while Peptinophilus was associated with anal HPV infections. Although more analyses are needed, our data suggests cervical and anal bacteria are associated to HPV infections which could pave the way to the development of early detection methods or novel probiotics for in women living in Puerto Rico. Citation Format: Frances Vazquez-Sanchez, Gilmary Ortiz, Ana P. Ortiz, Filipa Godoy-Vitorino. The microbiota associated to cervical and anal HPV infections in a Hispanic population [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4216.","PeriodicalId":20357,"journal":{"name":"Prevention, Early Detection, and Interception","volume":"45 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88089564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}